Joel Greenblatt’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.14M | Sell |
3,610
-562
| -13% | -$132K | ﹤0.01% | 1322 |
|
|
2026
Q1 | $833K | Sell |
4,172
-5,174
| -55% | -$1.02M | ﹤0.01% | 1363 |
|
|
2025
Q4 | $1.77M | Sell |
9,346
-129
| -1% | -$24.8K | 0.01% | 1074 |
|
|
2025
Q3 | $1.68M | Buy |
+9,475
| New | +$1.41M | 0.01% | 1049 |
|
|
2025
Q2 | – | Sell |
-6,912
| Closed | -$727K | – | 1710 |
|
|
2025
Q1 | $727K | Buy |
+6,912
| New | +$782K | 0.01% | 1101 |
|
|
2024
Q1 | – | Sell |
-4,183
| Closed | -$299K | – | 1424 |
|
|
2023
Q4 | $299K | Sell |
4,183
-3,300
| -44% | -$195K | 0.01% | 1139 |
|
|
2023
Q3 | $448K | Sell |
7,483
-1,799
| -19% | -$118K | 0.01% | 993 |
|
|
2023
Q2 | $669K | Buy |
9,282
+5,037
| +119% | +$378K | 0.01% | 887 |
|
|
2023
Q1 | $312K | Buy |
+4,245
| New | +$302K | 0.01% | 1115 |
|
|
2022
Q4 | – | Sell |
-7,282
| Closed | -$391K | – | 1268 |
|
|
2022
Q3 | $391K | Buy |
7,282
+2,244
| +45% | +$132K | 0.01% | 905 |
|
|
2022
Q2 | $280K | Sell |
5,038
-2,304
| -31% | -$131K | 0.01% | 962 |
|
|
2022
Q1 | $515K | Buy |
7,342
+1,799
| +32% | +$131K | 0.02% | 794 |
|
|
2021
Q4 | $534K | Buy |
5,543
+1,685
| +44% | +$156K | 0.02% | 753 |
|
|
2021
Q3 | $335K | Sell |
3,858
-249
| -6% | -$19.3K | 0.01% | 780 |
|
|
2021
Q2 | $336K | Buy |
4,107
+843
| +26% | +$70.1K | 0.01% | 803 |
|
|
2021
Q1 | $310K | Sell |
3,264
-2,691
| -45% | -$254K | 0.01% | 831 |
|
|
2020
Q4 | $369K | Buy |
+5,955
| New | +$340K | 0.01% | 784 |
|
|
2020
Q1 | – | Sell |
-3,956
| Closed | -$257K | – | 1148 |
|
|
2019
Q4 | $257K | Buy |
3,956
+550
| +16% | +$36.8K | ﹤0.01% | 982 |
|
|
2019
Q3 | $212K | Sell |
3,406
-100,262
| -97% | -$6.29M | ﹤0.01% | 998 |
|
|
2019
Q2 | $7.38M | Buy |
103,668
+62,896
| +154% | +$4.63M | 0.12% | 243 |
|
|
2019
Q1 | $3.2M | Buy |
40,772
+14,231
| +54% | +$1.08M | 0.05% | 416 |
|
|
2018
Q4 | $2.25M | Sell |
26,541
-18,040
| -40% | -$1.92M | 0.03% | 467 |
|
|
2018
Q3 | $7.63M | Buy |
44,581
+22,153
| +99% | +$3.34M | 0.11% | 267 |
|
|
2018
Q2 | $2.9M | Sell |
22,428
-3,717
| -14% | -$415K | 0.04% | 425 |
|
|
2018
Q1 | $2.69M | Sell |
26,145
-57,371
| -69% | -$5.67M | 0.04% | 452 |
|
|
2017
Q4 | $7.13M | Buy |
+83,516
| New | +$7.24M | 0.1% | 293 |
|
|
2017
Q2 | – | Sell |
-188,752
| Closed | -$12.5M | – | 1032 |
|
|
2017
Q1 | $12.5M | Buy |
188,752
+134,306
| +247% | +$8.84M | 0.16% | 217 |
|
|
2016
Q4 | $3.45M | Sell |
54,446
-6,838
| -11% | -$432K | 0.04% | 437 |
|
|
2016
Q3 | $3.9M | Sell |
61,284
-53,924
| -47% | -$3.96M | 0.05% | 397 |
|
|
2016
Q2 | $8.57M | Buy |
115,208
+80,227
| +229% | +$5.95M | 0.1% | 307 |
|
|
2016
Q1 | $2.34M | Buy |
+34,981
| New | +$2.13M | 0.03% | 559 |
|
|
2015
Q1 | – | Sell |
-6,037
| Closed | -$200K | – | 970 |
|
|
2014
Q4 | $200K | Sell |
6,037
-878,904
| -99% | -$28.6M | ﹤0.01% | 914 |
|
|
2014
Q3 | $25.9M | Buy |
884,941
+795,987
| +895% | +$26.4M | 0.26% | 143 |
|
|
2014
Q2 | $3.46M | Buy |
+88,954
| New | +$3.61M | 0.04% | 450 |
|
|
2014
Q1 | – | Sell |
-22,126
| Closed | -$726K | – | 1047 |
|
|
2013
Q4 | $726K | Buy |
22,126
+12,290
| +125% | +$400K | 0.02% | 688 |
|
|
2013
Q3 | $266K | Buy |
+9,836
| New | +$277K | 0.01% | 811 |
|
Other funds holding LGND
JT
CAM
Joel Greenblatt's LGND Position: Q2 2026 in Review
Joel Greenblatt reduced its Ligand Pharmaceuticals (LGND) stake by 13% in Q2 2026, selling an estimated $132K and leaving 3,610 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1322.
Joel Greenblatt first reported a position in LGND in Q3 2013 and has held it in 36 quarters since. The position peaked at $25.9M in Q3 2014. 413 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Joel Greenblatt held 3,610 shares of Ligand Pharmaceuticals worth $1.14M as of Q2 2026.
- Joel Greenblatt sold 562 Ligand Pharmaceuticals shares in Q2 2026, an estimated $132K.
- Ligand Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1322 holding.
- Joel Greenblatt first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 36 quarters since.
- Joel Greenblatt's Ligand Pharmaceuticals position peaked at $25.9M in Q3 2014.
- 413 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.